Provided by Tiger Trade Technology Pte. Ltd.

Prelude Therapeutics Inc

6.63
+0.13002.00%
Post-market: 6.690.0600+0.90%19:32 EDT
Volume:519.21K
Turnover:3.44M
Market Cap:528.03M
PE:-9.23
High:6.82
Open:6.56
Low:6.40
Close:6.50
52wk High:6.82
52wk Low:0.9807
Shares:79.64M
Float Shares:4.56M
Volume Ratio:0.67
T/O Rate:11.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7183
EPS(LYR):-1.2929
ROE:-57.73%
ROA:-27.15%
PB:3.95
PE(LYR):-5.13

Loading ...

Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M

Benzinga Earnings
·
May 12

Prelude Therapeutics Q1 net loss narrows as expenses fall

Reuters
·
May 12

BRIEF-Prelude Therapeutics Q1 EPS USD -0.13

Reuters
·
May 12

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 12

Prelude Therapeutics Q1 Operating Expenses USD 18.757 Million

THOMSON REUTERS
·
May 12

Prelude Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
May 08

Prelude Therapeutics Initiated at Buy by D. Boral Capital

Dow Jones
·
May 04

Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers

TIPRANKS
·
May 03

Prelude Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
May 01

Prelude Therapeutics initial beneficial ownership statement names RA Capital Management

Reuters
·
Apr 29

Prelude Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 27

Prelude Therapeutics Incorporated : H.c. Wainwright Raises Target Price to $8 From $5

THOMSON REUTERS
·
Apr 27

Massive Insider Buying Spree Signals Bold Confidence in Prelude Therapeutics

TIPRANKS
·
Apr 24

OrbiMed Advisors acquires $12.5 million Prelude Therapeutics common shares

Reuters
·
Apr 24

Prelude Therapeutics Highlights Promising PRT13722 Preclinical Results

TIPRANKS
·
Apr 20

Prelude Therapeutics presents new preclinical data from PRT13722 study

TIPRANKS
·
Apr 20

Prelude Therapeutics Inc - Pricing of 18.01 Mln Shares of Common Stock at $4.44 per Share

THOMSON REUTERS
·
Apr 20

Press Release: Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering

Dow Jones
·
Apr 20

Prelude Therapeutics targets mid-2026 IND filing for PRT13722 breast cancer trial

Reuters
·
Apr 20

Press Release: Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer

Dow Jones
·
Apr 15